Exicure, Inc. (Nasdaq: XCUR) announced on November 20, 2026, that it has entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. The agreement is intended to expand Exicure’s business into medical device technologies designed to assist patients with Parkinson’s disease.
The agreement focuses on X-CUE, an augmented-reality smart-glasses technology developed over more than a decade. The device is designed to assist patients experiencing freezing of gait, a condition that significantly affects mobility. According to the press release, X-CUE has completed its product development phase for its latest, third-revised version and is ready for planned clinical trials. The anticipated clinical evaluation period is approximately six months.
Under the terms of the agreement, Exicure intends to acquire an equity interest in NeuroQ ranging from 20% to 100%. The acquisition will be conducted primarily through the issuance of Exicure common shares in exchange for NeuroQ shares held by Laonz. The final percentage, share exchange ratio, and other terms are to be determined through subsequent written agreements, subject to corporate and regulatory approvals and Nasdaq requirements.
Following the completion of the proposed share acquisition, Exicure intends to provide up to US$500,000 in development funding. This funding is intended to support X-CUE’s clinical evaluation, regulatory advancement, manufacturing preparation, and commercialization initiatives. Laonz has completed the transfer of the X-CUE business, including related intellectual property, technology, assets, and business rights, to NeuroQ. NeuroQ will lead the continued development, clinical evaluation, regulatory approval, and commercialization of X-CUE, with strategic support from Exicure.
Exicure’s Chief Executive Officer, Jung Soo Kim, stated that the agreement allows the company to expand into innovative medical device technologies to address unmet needs in Parkinson’s disease. The company noted that the technology has a long development history and is currently prepared for clinical evaluation.